Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Index
-
Market Cap
269.72M
Enterprise Value
228.64M
Income
-71.14M
Sales
0.30M
Book/sh
-0.31
Cash/sh
0.26
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
112
IPO
Dec 08, 1998
P/E
-
Forward P/E
-
PEG
-
P/S
899.08
P/B
-
P/C
5.58
P/FCF
-
EV/EBITDA
-
EV/Sales
762.14
Quick Ratio
0.57
Current Ratio
0.57
Debt/Eq
-
LT Debt/Eq
-
Option/Short
Yes / Yes
EPS (ttm)
-0.80
EPS next Y
-0.18
EPS next Q
-0.13
EPS this Y
50.46%
EPS next Y
80.30%
EPS next 5Y
82.32%
EPS past 3/5Y
49.51% 32.44%
Sales past 3/5Y
-81.47% -61.18%
EPS Y/Y TTM
68.94%
Sales Y/Y TTM
63.93%
EPS Q/Q
42.79%
Sales Q/Q
-
Insider Own
0.38%
Insider Trans
0.00%
Inst Own
53.72%
Inst Trans
11.01%
ROA
-109.84%
ROE
-409.87%
ROIC
-
Gross Margin
-919.42%
Oper. Margin
-25953.76%
Profit Margin
-23798.90%
SMA20
18.99%
SMA50
21.52%
SMA200
14.18%
Trades
Shs Outstand
110.18M
Shs Float
-
52W High
2.72 -47.06%
52W Low
0.56 155.68%
Volatility
13.88% 19.16%
ATR (14)
0.22
RSI (14)
55.52
Beta
1.58
Rel Volume
0.04
Avg Volume
10.88M
Volume
24,141
Perf Week
-4.64%
Perf Month
45.44%
Perf Quarter
20.00%
Perf Half Y
18.03%
Perf YTD
-17.24%
Perf Year
-29.76%
Perf 3Y
-70.73%
Perf 5Y
-98.36%
Perf 10Y
-98.46%
Prev Close
1.43
Price
1.44
Change %
0.70%
Consensus
Strong Buy
Avg. Price Target
$6.33
Implied Upside
+339.6%
Analysts10incl. previous ratings
Rating Distribution5 Buy · 3 Hold · 2 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Nov 02, 2026Upgrade
HH.C. Wainwright
Neutral → Buy$5+247.2%
Aug 13, 2026Upgrade
JEF logoJJefferies
Hold → Buy$3+108.3%
Jul 09, 2025Initiated
PPiper Sandler
Overweight$5+247.2%
May 14, 2024Initiated
SStephens
Overweight$20+1,288.9%
Jan 25, 2024Upgrade
OPY logoOOppenheimer
Perform → Outperform$4+177.8%
Nov 09, 2022Downgrade
MMaxim Group
Buy → Hold
Nov 01, 2022Downgrade
BAC logoBBofA Securities
Neutral → Underperform$2+38.9%
Jul 19, 2022Resumed
RY logoRRBC Capital Mkts
Sector Perform$5 → $4+177.8%
May 11, 2022Downgrade
OPY logoOOppenheimer
Outperform → Perform
Jan 21, 2022Upgrade
BAC logoBBofA Securities
Underperform → Neutral$8 → $10+594.4%
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
CEODr. Jacqueline E. Shea Ph.D.
Chief Financial OfficerMr. Peter D. Kies
M.B.A.Dr. Michael Sumner B.S.
Chief Scientific Officer & Chairman of the Scientific Advisory BoardDr. Laurent M. Humeau Ph.D.
General CounselMr. Robert L. Crotty J.D.